- Developed a ‘Niclosamide-based multi-treatment drug’ that may concurrently deal with mosquito-borne viral infections similar to 4 serotypes of dengue virus, Zika, Chikungunya, and Yellow (OTC:) Fever.
- Accelerating preparations for dengue fever basket medical trial scheduled to be performed in
Brazil .
To successfully deal with dengue fever, the antiviral should be administered early, earlier than the viral load will increase considerably. For early administration, the remedy should be efficient not solely in opposition to dengue fever but in addition in opposition to different mosquito-borne viral illnesses with related signs, similar to Zika, Chikungunya, and Yellow Fever. Leveraging its patented know-how, Hyundai Bioscience has enhanced the bioavailability of niclosamide, enabling it to deal with arbovirus infections attributable to Zika, Chikungunya, and Yellow Fever viruses along with dengue fever. Lately, the corporate has succeeded in growing a “niclosamide-based multi-treatment for mosquito-borne viral infections” that may preserve an IC50 within the blood to inhibit the replication of those viruses.
Presently, there isn’t any remedy for dengue fever. The dengue virus has 4 serotypes (DENV-1, DENV-2, DENV-3, DENV-4), every with completely different IC50 values. The IC50 values for Zika, Chikungunya, and Yellow Fever viruses, that are additionally mosquito-borne, differ as properly. Hyundai Bioscience’s multi-treatment drug candidate is the world’s first to keep up niclosamide’s blood focus above the IC50 worth of all 4 serotypes of dengue virus in addition to Zika, Chikungunya, and Yellow Fever viruses.
Hyundai Bioscience has formulated the multi-treatment antiviral right into a pill type to facilitate mass manufacturing and to make it handy for transportation and storage.
Hyundai Bioscience has determined to conduct the dengue fever basket medical trial in
The dengue fever medical trial, to be performed by Hyundai Bioscience USA in
About Hyundai Bioscience
Hyundai Bioscience is a biotechnology firm that develops new medication based mostly on its novel drug supply system applied sciences to ship energetic substances safely and effectively to focused areas of the human physique. Based in 2000, Hyundai Bioscience focuses on repurposing or increasing indications of current medication utilizing its proprietary organic-inorganic hybrid applied sciences. Hyundai Bioscience is a public firm listed on KOSDAQ (image: 048410) in
For extra info, please contact Ms.